A man checks his blood sugar level using a glucometer. China has around 120 million diagnosed diabetes patients. Photo: Shutterstock

Why are investors offloading Hua Medicine stock which is close to launching a novel diabetes drug?

  • George Lin, Hua Medicine’s chief financial officer, says results for dorzagliatin are good and has advantages over existing diabetes drugs on the market
  • Company is targeting a launch for the drug in 2021
Topic |   Pharmaceuticals

TOP PICKS

A man checks his blood sugar level using a glucometer. China has around 120 million diagnosed diabetes patients. Photo: Shutterstock
READ FULL ARTICLE